Synthroid hashimoto's
Pro Research Analysisby 
Searched over 200M research papers for "synthroid hashimoto's"
Synthroid and Hashimoto's Thyroiditis: Treatment Insights
Introduction to Hashimoto's Thyroiditis and Hypothyroidism
Hashimoto's thyroiditis is an autoimmune disorder and the most common cause of hypothyroidism. This condition leads to the destruction of thyroid tissue by the immune system, resulting in decreased production of thyroid hormones. Patients with Hashimoto's thyroiditis typically require lifelong thyroid hormone replacement therapy to manage their condition .
Synthroid (Levothyroxine) as the Preferred Treatment
Levothyroxine, commonly known by the brand name Synthroid, is the synthetic form of the thyroid hormone thyroxine (T4). It is the drug of choice for treating hypothyroidism, including cases caused by Hashimoto's thyroiditis. Synthroid effectively replaces the deficient hormone, helping to normalize thyroid function and alleviate symptoms of hypothyroidism .
Challenges in Treatment: Hormone-Resistant Hypothyroidism
In some cases, patients with Hashimoto's thyroiditis may exhibit resistance to standard thyroid hormone treatments. This resistance can be due to various factors, including the presence of thyroid hormone autoantibodies. For instance, a case study of an 8-year-old girl with severe hypothyroidism revealed high levels of free thyroxine (T4) and thyroid-stimulating hormone (TSH), along with antimicrosomal antibodies. The presence of T4 autoantibodies led to inaccurate readings of free T4 levels, complicating the treatment process. However, normalization of free T4 levels through equilibrium dialysis allowed for a successful switch from triiodothyronine (Cytomel) to Synthroid, maintaining therapeutic efficacy .
Drug Resistance and Efflux Transporters
Another challenge in treating Hashimoto's thyroiditis is the occurrence of multidrug resistance, which can be linked to the high expression of efflux transporters such as ABCG2/BCRP. These transporters can reduce the effectiveness of orally administered medications by accelerating their efflux from the small intestine. A reported case highlighted a patient with Hashimoto's thyroiditis who exhibited resistance to multiple drugs, including levothyroxine. The study found that crushing levothyroxine tablets, as opposed to administering them intact, significantly improved the patient's response to the medication. This suggests that efflux transporter activity can play a crucial role in treatment resistance and that alternative administration methods may enhance drug efficacy .
Conclusion
Synthroid (levothyroxine) remains the cornerstone of treatment for hypothyroidism due to Hashimoto's thyroiditis. However, clinicians must be aware of potential challenges such as hormone resistance and the role of efflux transporters in drug efficacy. Understanding these factors can help optimize treatment strategies, ensuring better management of this common thyroid disorder.
Sources and full results
Most relevant research papers on this topic
Thyroxine and Triiodothyronine Autoantibodies in Hashimoto's Thyroiditis with Severe Hormone- Resistant Hypothyroidism
Hashimoto's thyroiditis with severe hypothyroidism can be managed by changing treatment from Cytomel to Synthroid, allowing for therapeutic efficacy.
A case of Hashimoto's thyroiditis with multiple drug resistance and high expression of efflux transporters.
High expression of ABCG2/BCRP in the small intestine contributes to treatment-resistant Hashimoto's thyroiditis, and crushed tablets may be more effective for some patients.
Hashimotos' thyroiditis: Epidemiology, pathogenesis, clinic and therapy.
Hashimoto's thyroiditis is a common autoimmune thyroid disorder caused by a combination of genetic susceptibility and environmental factors, leading to hypothyroidism in iodine-sufficient areas.
Clinical characteristics of paediatric Hashimoto's encephalopathy.R2 clean.
Hashimoto's encephalopathy in children often causes epilepsy, behavioral problems, decline in school performance, and hallucinations, with steroids being the main treatment and about one in ten experiencing late sequelae.
DOI